Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

OncoAlert and ecancer weekly roundup for September 14-19, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for September 14-19, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer

Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer ( Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan )

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1...

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC...

Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers

Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

Estimate of the 2-year oncology workload generated by each new patient: A real...

Dr Silvio Ken Garattini - University of Udine, Udine, Italy

Estimate of the 2-year oncology workload generated by each new patient: A real-world study ( Dr Silvio Ken Garattini - University of Udine, Udine, Italy )

Amivantamab lazertinib and other novel combinations in EGFR positive advanced...

Dr Alex Spira and Dr Joshua Sabari

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )

Impact of COVID-19 pandemic on cancer care: A global collaborative study

Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi...

Impact of COVID-19 pandemic on cancer care: A global collaborative study ( Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia )

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer

Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )

Personalised molecularly matched therapies for carcinomas of unknown primary

Dr Jacob Adashek - University of South Florida, Tampa, USA

Personalised molecularly matched therapies for carcinomas of unknown primary ( Dr Jacob Adashek - University of South Florida, Tampa, USA )

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated...

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

More from ecancer